Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
NeoImmuneTech
AstraZeneca
I-Mab Biopharma US Limited
City of Hope Medical Center
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
Alaunos Therapeutics
Incyte Corporation
National Cancer Institute (NCI)
Elicio Therapeutics
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
Sichuan Enray Pharmaceutical Sciences Company
Institut Bergonié
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
M.D. Anderson Cancer Center
Elevation Oncology
UNC Lineberger Comprehensive Cancer Center
Stanford University
Sellas Life Sciences Group
Pfizer
NantCell, Inc.
NantCell, Inc.
Pfizer
NextCure, Inc.
ADC Therapeutics S.A.
Cancer Research and Biostatistics Clinical Trials Consortium
Exelixis
Pfizer
Pfizer
University Hospital, Ghent
pharmaand GmbH
M.D. Anderson Cancer Center
Hoffmann-La Roche
City of Hope Medical Center
OncoNano Medicine, Inc.
Revolution Medicines, Inc.
Herlev Hospital
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Incyte Corporation
Five Prime Therapeutics, Inc.
Incyte Corporation
Seagen Inc.
Seagen Inc.